North America Cardiometabolic Diseases Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Cardiovascular disease (CVD), Type 2 diabetes, Hypertension, and Obesity), Treatment (ACE Inhibitors, Diuretics, Glucophage, and Others), Dosage (Tablet, and Injection), Route of Administration (Oral, and Intravenous), End Users (Hospital, Clinic, and Homecare Settings), and Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy)

No. of Pages: 192    |    Report Code: TIPRE00026139    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Cardiometabolic Diseases Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Cardiometabolic Diseases Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Cardiometabolic Diseases Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1
  • 5.1.2 Growing prevalence of lifestyle diseases.
  • 5.1.3 Rising geriatric population globally.
  • 5.1.4 Increasing awareness of heart health.
5.2 Market Opportunities
  • 5.2.1
  • 5.2.2 Emerging telehealth management solutions.
  • 5.2.3 Personalized medicine in diagnostics.
  • 5.2.4 Rising demand for wearable monitors.
5.3 Future Trends
  • 5.3.1
  • 5.3.2 AI-driven predictive health analytics.
  • 5.3.3 Increased remote patient monitoring.
  • 5.3.4 Focus on preventive healthcare solutions.
5.4 Impact of Drivers and Restraints

6. North America Cardiometabolic Diseases Market Regional Analysis

6.1 North America Cardiometabolic Diseases Market Overview
6.2 North America Cardiometabolic Diseases Market Revenue 2019-2028 (US$ Million)
6.3 North America Cardiometabolic Diseases Market Forecast Analysis

7. North America Cardiometabolic Diseases Market Analysis – by Type

7.1 Cardiovascular disease
  • 7.1.1 Overview
  • 7.1.2 Cardiovascular disease: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Type 2 diabetes
  • 7.2.1 Overview
  • 7.2.2 Type 2 diabetes: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Hypertension
  • 7.3.1 Overview
  • 7.3.2 Hypertension: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Obesity
  • 7.4.1 Overview
  • 7.4.2 Obesity: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Cardiometabolic Diseases Market Analysis – by Treatment

8.1 ACE Inhibitors
  • 8.1.1 Overview
  • 8.1.2 ACE Inhibitors: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Diuretics
  • 8.2.1 Overview
  • 8.2.2 Diuretics: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Glucophage
  • 8.3.1 Overview
  • 8.3.2 Glucophage: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Cardiometabolic Diseases Market Analysis – by Dosage

9.1 Tablet
  • 9.1.1 Overview
  • 9.1.2 Glucophage: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Injection
  • 9.2.1 Overview
  • 9.2.2 Glucophage: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Cardiometabolic Diseases Market – North America Analysis

10.1 North America
  • 10.1.1 North America Cardiometabolic Diseases Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.1.1.1 North America Cardiometabolic Diseases Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 US: North America Cardiometabolic Diseases Market Breakdown, by Type
    • 10.1.1.1.2 US: North America Cardiometabolic Diseases Market Breakdown, by Treatment
    • 10.1.1.1.3 US: North America Cardiometabolic Diseases Market Breakdown, by Dosage
  • 10.1.1.2 Canada: North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Canada: North America Cardiometabolic Diseases Market Breakdown, by Type
    • 10.1.1.2.2 Canada: North America Cardiometabolic Diseases Market Breakdown, by Treatment
    • 10.1.1.2.3 Canada: North America Cardiometabolic Diseases Market Breakdown, by Dosage
  • 10.1.1.3 Mexico : North America Cardiometabolic Diseases Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Cardiometabolic Diseases Market Breakdown, by Type
    • 10.1.1.3.2 Mexico : North America Cardiometabolic Diseases Market Breakdown, by Treatment
    • 10.1.1.3.3 Mexico : North America Cardiometabolic Diseases Market Breakdown, by Dosage

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Cardiometabolic Diseases Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Eli Lilly and Company.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 Bayer AG
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Arrowhead Pharmaceuticals, Inc
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Novartis AG
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Boehringer Ingelheim International Gmbh
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Novo Nordisk A/S
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 AstraZeneca
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Alnylam Pharmaceuticals, Inc.
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 Cardax, Inc.
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Kowa Company, Ltd.
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - N Market

  1. Eli Lilly and Company.   
  2. Bayer AG             
  3. Arrowhead Pharmaceuticals, Inc    
  4. Novartis AG         
  5. Boehringer Ingelheim International Gmbh
  6. Novo Nordisk A/S            
  7. AstraZeneca         
  8. Alnylam Pharmaceuticals, Inc.
  9. Cardax, Inc.
  10. Kowa Company, Ltd.
north-america-cardiometabolic-diseases-market